 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- 800 TCR - T / Cure Biosci
Improving killing of renal cell carcinoma through the combined effects of TCR engineered CD4+ and CD8+ T cells (Section 39) - Mar 5, 2024 - Abstract #AACR2024AACR_5067;
P1
In conclusion, these data show that CD4+ BZ-4 T cells transfected with the CD8 co-receptor acquire the ability to lyse RCC tumors at levels comparable to that observed in CD8+ BZ-4 T cells. Additional experiments are planned to evaluate whether mixtures of CD8+ BZ-4 T cells with CD4+ BZ-4-8 T cells will augment the ability of TCR modified T cells to proliferate in vivo and kill human RCC tumors compared to CD8+ BZ-4 T cells alone in tumor bearing NSG mice.
- 800 TCR - T / Cure Biosci
Final results of a phase I trial of HERV-E TCR transduced T cells for the treatment of HLA-A*11 patients with metastatic clear cell renal cell carcinoma (mccRCC). (Level 1, West Hall; Poster Bd # H17) - Dec 13, 2023 - Abstract #ASCOGU2024ASCO_GU_778;
P1
Infused HERV-E T cells were detectable transiently in vivo and induce effector cytokine production. Our initial results support the further development of HERV-E-directed therapies that focus on methods to improve in vivo persistence of TCR engineered T-cells and to target HERV-E antigens expressed on more commonly expressed HLA alleles.
- | 800 TCR - T / Cure Biosci
Enrollment closed, Enrollment change, Trial primary completion date, Metastases: HERV-E TCR Transduced Autologous T Cells in People With Metastatic Clear Cell Renal Cell Carcinoma (clinicaltrials.gov) - Nov 13, 2023
P1, N=16, Active, not recruiting, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Our initial results support the further development of HERV-E-directed therapies that focus on methods to improve in vivo persistence of TCR engineered T-cells and to target HERV-E antigens expressed on more commonly expressed HLA alleles. Recruiting --> Active, not recruiting | N=24 --> 16 | Trial primary completion date: Apr 2024 --> Oct 2023
- Opdivo (nivolumab) / Ono Pharma, BMS, 800 TCR - T / Cure Biosci, Yervoy (ipilimumab) / Ono Pharma, BMS
Phase I results of human endogenous retrovirus type-E (HERV-E) TCR transduced T-cells in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC). (On Demand | Hall A; Poster Bd # 391) - Apr 26, 2023 - Abstract #ASCO2023ASCO_2317;
P1
The manufacturing method utilized produced large numbers of highly purified CD8+ HERV-E reactive T-cells that were not associated with any dose limiting toxicities when given at doses up to 5x107 cells/kg. For pts in DL4, HERV-E TCR were observed to proliferate in vivo, traffic to a metastatic site, and induce tumor regression in one mccRCC pts.
- | 800 TCR - T / Cure Biosci
Trial completion date, Trial primary completion date, Metastases: HERV-E TCR Transduced Autologous T Cells in People With Metastatic Clear Cell Renal Cell Carcinoma (clinicaltrials.gov) - Sep 10, 2022
P1, N=24, Recruiting, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
For pts in DL4, HERV-E TCR were observed to proliferate in vivo, traffic to a metastatic site, and induce tumor regression in one mccRCC pts. Trial completion date: Dec 2022 --> Dec 2032 | Trial primary completion date: Dec 2022 --> Apr 2024
- | 800 TCR - T / Cure Biosci
Trial completion date, Trial primary completion date, Metastases: HERV-E TCR Transduced Autologous T Cells in People With Metastatic Clear Cell Renal Cell Carcinoma (clinicaltrials.gov) - Sep 27, 2021
P1, N=24, Recruiting, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Trial completion date: Dec 2022 --> Dec 2032 | Trial primary completion date: Dec 2022 --> Apr 2024 Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Dec 2022
- | 800 TCR - T / Cure Biosci
Trial completion date, Trial primary completion date, Metastases: HERV-E TCR Transduced Autologous T Cells in People With Metastatic Clear Cell Renal Cell Carcinoma (clinicaltrials.gov) - Jan 14, 2021
P1, N=24, Recruiting, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Dec 2022 Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Dec 2020 --> Dec 2021
- | 800 TCR - T / Cure Biosci
Trial initiation date, Metastases: HERV-E TCR Transduced Autologous T Cells in People With Metastatic Clear Cell Renal Cell Carcinoma (clinicaltrials.gov) - Mar 3, 2018
P1, N=24, Recruiting, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Dec 2020 --> Dec 2021 Initiation date: Mar 2018 --> Mar 2018
- | 800 TCR - T / Cure Biosci
Enrollment open, Metastases: HERV-E TCR Transduced Autologous T Cells in People With Metastatic Clear Cell Renal Cell Carcinoma (clinicaltrials.gov) - Jan 11, 2018
P1, N=24, Recruiting, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Initiation date: Mar 2018 --> Mar 2018 Not yet recruiting --> Recruiting
- | 800 TCR - T / Cure Biosci
Metastases: HERV-E TCR Transduced Autologous T Cells in People With Metastatic Clear Cell Renal Cell Carcinoma (clinicaltrials.gov) - Nov 27, 2017
P1, N=24, Not yet recruiting, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)